Prostate Cancer News

Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets

Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets

The regimen did not improve survival and increased bone fractures.

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer

In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.

Comparison of Multimodal Approaches in High-Risk Prostate Cancer

Comparison of Multimodal Approaches in High-Risk Prostate Cancer

Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.

High Mutation Load Seen in the High-Risk Prostate Tumors of African Men

High Mutation Load Seen in the High-Risk Prostate Tumors of African Men

Differences in TMB between African and European patients show that "racial mutational disparity is not a technical or computational artifact," according to authors.

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Prostate Cancer Drug Resistance Mediated by Epigenetic Changes

Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Study Zeroes in on Cause of Castration-Resistant Prostate Cancer

Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

Heavy Alcohol Intake in Early Life May Significantly Increase Odds of High-Grade Prostate Cancer

Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

Active Surveillance May Be a Good Option for Younger Men with Prostate Cancer

The effect of age on outcomes in active surveillance is not well reported and requires further study.

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

Beverages Sweetened With Added Sugars May Increase the Risk of Prostate Cancer

Some prior evidence has linked increased sugar consumption to cancer development, but its impact on prostate cancer is unknown.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk Prostate Cancer

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

High-Intensity Focused Ultrasound Therapy May Improve Survival in Nonmetastatic Prostate Cancer

Focal therapy targets may potentially reduce adverse events and provide better cancer control, but previous studies have been limited in scope.

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Enzalutamide Postpones Metastasis for a Subset of High-Risk Patients With Prostate Cancer

Treatment with enzalutamide decreased the risk of metastasis or death by 71% in patients diagnosed with nonmetastatic castration-resistant prostate cancer.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone for mCRPC May Benefit Patients Who Are Black More Than Patients Who Are White

Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.

PET/CT Accurately Localizes Recurrent Prostate Cancer

PET/CT Accurately Localizes Recurrent Prostate Cancer

Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

Post-Radiotherapy Docetaxel for Intermediate-, High-Risk Prostate Cancer Is Not Beneficial

A phase 3 trial involving men treated with radiotherapy for intermediate- or high-risk prostate cancer revealed no significant difference in biochemical disease-free survival.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs